Latest:
Dr. Hansen on the Utilization of BCMA-Directed Therapy in Multiple Myeloma
Doris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center
C. Ola Landgren, MD, PhD, is a professor of medicine and chief of the Division of Myeloma in the Department of Medicine at the University of Miami Miller School of Medicine; director of the Sylvester Myeloma Institute; and co-leader of the Translational and Clinical Oncology Program and Paul J. DiMare Endowed Chair in immunotherapy at the Sylvester Comprehensive Cancer Center.
Latest:
Dr Landgren on Considerations Surrounding the Current Treatment Paradigm for Smoldering Multiple Myeloma
C. Ola Landgren, MD, PhD, discusses the current treatment paradigm for patients with smoldering multiple myeloma.
Ruben Raychaudhuri, MD
Physician, Fred Hutch, Assistant Professor, Clinical Research Division, Fred Hutch, Assistant Professor, Division of Hematology and Oncology, University of Washington School of Medicine
Latest:
Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD
Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.
Cesar Augusto Perez, MD
Latest:
First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase
Presented by Dr. Cesar Perez, this first-in-human phase 1 study of BG-C9074—a B7-H4–targeting antibody-drug conjugate—demonstrated early antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors.
Quoc-Dien Trinh, MD
Quoc-Dien Trinh, MD, MBA, is chair of the Department of Urology at the University of Pittsburgh School of Medicine and UPMC.
Latest:
Dr Trinh on Outcomes for Darolutamide Plus ADT in Black Patients With mHSPC
Quoc-Dien Trinh, MD, MBA, discusses outcomes for darolutamide plus ADT in Black patients with metastatic hormone-sensitive prostate cancer.
Andrea Casadei Gardini, MD, San Raffaele Research Hospital
Latest:
Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line
Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.
Marla D. Lipsyc-Sharf, MD
Latest:
Patient Selection and Implementation Strategies for MRD Testing
Panelists emphasize that as circulating tumor DNA (ctDNA) testing becomes more integrated into clinical practice, careful interpretation, tailored testing schedules, and ongoing provider education are key to its effective use in personalized breast cancer care.
Aditya Bardia, MD
Latest:
Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial
Aditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.